7 results
Anti-IL6 Agents (Tocilizumab, Siltuximab) in COVID19

IL-6 activates T cells and macrophages, among other cell types (see
Siltuximab) in COVID19 ... other cell types (see ... “Cytokine Activation ... Syndrome” IL-6 ... #Pharmacology #Management
CNS Manifestations of Systemic Lupus Erythematosus (SLE)

Clinical Manifestations: Demyelinating Syndrome, Headache, Movement disorders, Seizure disorders, Aseptic
CNS Manifestations ... Demyelinating Syndrome ... Disease, PRES Pathophysiology ... #rheumatology # ... cerebritis #diagnosis #management
Macrophage Activation Syndrome (MAS)
Classified among the secondary or acquired forms of haemophagocytic lymphohistiocytosis (sHLH)

What?
A subset of
Macrophage Activation ... Syndrome (MAS) ... nervous system (CNS ... erythematosus [SLE ... #Management #Hematology
SLE (Systemic Lupus Erythematosus)

Suspect:
Clinical evidence of (fatigue, rash, photosensitivity, inflammatory arthritis, weight loss, and fever) and
small and large bowel ... erythematosus (NPSLE): • May ... CNS • Headache ... vein thrombosis Hematologic ... Chronic B-cell activation
Leukostasis vs Tumor Lysis Syndrome
Leukostasis:
 • Pathophysiology: Large, immature blasts and high WBC count cause hyperviscosity
Leukostasis: • Pathophysiology ... : - Neuro: AMS ... limb ischemia, bowel ... TLS #diagnosis #management ... #hematology
Transverse Myelitis Overview

Focal inflammatory disorder of the spinal cord resulting in rapid onset of weakness, sensory
alterations, and bowel ... monophasic Pathophysiology ... • Excessive activation ... that results in CNS ... Myelitis #diagnosis #management
TAFRO

TAFRO syndrome was first described in 2010, standing for:
- Thrombocytopenia
- Anasarca
- Fever
- Reticulin fibrosis
- Organomegaly

TAFRO syndrome
erythematosus (SLE ... cell lymphoma Pathophysiology ... histopathologic changes in LNs ... TAFRO #diagnosis #management ... #rheumatology #